Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (NCT07013591) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
United States90 participantsStarted 2026-03-31
Plain-language summary
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years
✓. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
✓. At increased risk of postoperative complications based on ≥1 of the following:
✓. Age ≥65 years
✓. eGFR \<45 ml/min/1.73m2
✓. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery
✓. Diabetes mellitus and urine albumin-to-creatinine ratio \>30 mg/g creatinine
✓. Peripheral arterial disease
Exclusion criteria
✕. Any of the following laboratory abnormalities at the time of screening:
✕. ALT \>3-fold the upper limit of normal
✕. eGFR \<30 ml/min/1.73m2 or ESKD on dialysis
✕. Hemoglobin \<8 g/dl
✕. History of gastric bypass or malabsorption
✕. Active alcohol or illicit substance use in the prior 6 months